Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM EBITDA Multiple | 18.2x - 20.1x | 19.1x |
Selected Fwd EBITDA Multiple | 16.3x - 18.0x | 17.1x |
Fair Value | ﷼73.28 - ﷼80.72 | ﷼77 |
Upside | -4.8% - 4.8% | 0.0% |
Benchmarks | Ticker | Full Ticker |
Jana Medical Company | 9616 | SASE:9616 |
Scientific and Medical Equipment House Company | 4014 | SASE:4014 |
Professional Medical Expertise Company | 9574 | SASE:9574 |
Future Care Trading Co. | 9544 | SASE:9544 |
Ayyan Investment Company | 2140 | SASE:2140 |
Balsm Alofoq Medical Company | 9620 | SASE:9620 |
- | - | - |
Select LTM EBITDA Multiple | |||||||
Benchmark Companies | |||||||
9616 | 4014 | 9574 | 9544 | 2140 | 9620 | ||
SASE:9616 | SASE:4014 | SASE:9574 | SASE:9544 | SASE:2140 | SASE:9620 | ||
Historical EBITDA Growth | |||||||
5Y CAGR | NM- | -1.6% | NM- | NM- | NM- | NM- | |
3Y CAGR | NM- | -10.8% | 41.2% | -36.4% | NM- | NM- | |
Latest Twelve Months | NM | -32.8% | 24.8% | -29.7% | -178.9% | NM | |
Historical EBITDA Profit Margin | |||||||
5 Year Average Margin | 21.5% | 10.4% | 16.3% | 32.8% | -27.8% | 27.4% | |
Prior Fiscal Year | 17.6% | 11.1% | 15.9% | 28.3% | -38.6% | 27.2% | |
Latest Fiscal Year | 20.6% | 7.4% | 14.9% | 18.9% | -82.9% | 28.6% | |
Latest Twelve Months | 25.1% | 6.9% | 15.2% | 18.9% | -228.3% | 26.2% | |
Current Trading Multiples | |||||||
EV / LTM Revenue | 1.21x | 1.34x | 1.43x | 23.51x | 39.44x | 5.05x | |
EV / LTM EBITDA | 4.8x | 19.4x | 9.4x | 124.2x | -17.3x | 19.3x | |
EV / LTM EBIT | 4.9x | 23.0x | 10.5x | 145.0x | -28.4x | 23.5x | |
Low | Mid | High | |||||
Benchmark EV / LTM EBITDA | -17.3x | 9.4x | 124.2x | ||||
Historical EV / LTM EBITDA | 0.0x | NM | 0.0x | ||||
Selected EV / LTM EBITDA | 18.2x | 19.1x | 20.1x | ||||
(x) LTM EBITDA | 5 | 5 | 5 | ||||
(=) Implied Enterprise Value | 89 | 94 | 99 | ||||
(-) Non-shareholder Claims * | 3 | 3 | 3 | ||||
(=) Equity Value | 93 | 97 | 102 | ||||
(/) Shares Outstanding | 1.3 | 1.3 | 1.3 | ||||
Implied Value Range | 74.16 | 77.93 | 81.69 | ||||
FX Rate: SAR/SAR | 1.0 | 1.0 | 1.0 | Market Price | |||
Implied Value Range (Trading Cur) | 74.16 | 77.93 | 81.69 | 77.00 | |||
Upside / (Downside) | -3.7% | 1.2% | 6.1% |
Equity Waterfall | |||||||
Benchmark Companies | |||||||
(in millions) | 9616 | 4014 | 9574 | 9544 | 2140 | 9620 | |
Enterprise Value | 79 | 1,207 | 402 | 1,176 | 505 | 93 | |
(+) Cash & Short Term Investments | 1 | 66 | 7 | 56 | 647 | 5 | |
(+) Investments & Other | 0 | 0 | 0 | 6 | 169 | 0 | |
(-) Debt | (37) | (142) | (101) | (2) | (4) | (2) | |
(-) Other Liabilities | 0 | 6 | 0 | 0 | 0 | 0 | |
(-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
(-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
Value of Common Equity | 42 | 1,136 | 308 | 1,235 | 1,316 | 96 | |
(/) Shares Outstanding | 3.2 | 30.0 | 3.5 | 500.0 | 100.6 | 1.3 | |
Implied Stock Price | 13.20 | 37.88 | 88.00 | 2.47 | 13.08 | 77.00 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
Implied Stock Price (Trading Cur) | 13.20 | 37.88 | 88.00 | 2.47 | 13.08 | 77.00 | |
Trading Currency | SAR | SAR | SAR | SAR | SAR | SAR | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |